Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study

Ranjan Malhotra,1 Joseph Gira,2 Gregg J Berdy,1 Robert Brusatti11Ophthalmology Associates, 2Ophthalmology Consultants, St Louis, MO, USABackground: The purpose of this study was to evaluate the safety and tolerability of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic s...

Full description

Bibliographic Details
Main Authors:	Malhotra R, Gira J, Berdy GJ, Brusatti R
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-06-01
Series:	Clinical Ophthalmology
Online Access:	http://www.dovepress.com/safety-of-besifloxacin-ophthalmic-suspension-06-as-a-prophylactic-anti-a10033

Similar Items

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
by: Silverstein BE, et al.
Published: (2012-11-01)

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
by: Bucci FA Jr, et al.
Published: (2015-05-01)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
by: Morris TW, et al.
Published: (2011-09-01)

Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens
by: Comstock TL, et al.
Published: (2014-04-01)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
by: Nielsen SA, et al.
Published: (2013-04-01)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
by: Nielsen SA, et al.
Published: (2013-01-01)

Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis
by: S. Khimdas, et al.
Published: (2011-01-01)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
by: Haas W, et al.
Published: (2011-09-01)

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
by: Heleen H DeCory, et al.
Published: (2020-01-01)

Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones
by: Haas W, et al.
Published: (2013-05-01)

The Effect of Prophylactic Administration of Ketorolac Ophthalmic Suspension on Prevention of Surgically Induced Miosis in Patients Undergoing Cataract Surgery
by: Mehdi Sanatkar, et al.
Published: (2016-06-01)

Safety of prophylactic intracameral moxifloxacin ophthalmic solution after cataract surgery in patients with penetrating keratoplasty
by: Osman Sevki Arslan, et al.
Published: (2014-10-01)

To Study the Efficacy of Difluprednate Ophthalmic Emulsion and Prednisolone Acetate Ophthalmic Suspension on Post-operative Inflammation in Cataract Surgery
by: Punita Garg, et al.
Published: (2016-12-01)

Spectral Analysis and Structural Elucidation of Besifloxacin Hydrochloride
by: ZHANG Ming-guang, et al.
Published: (2018-09-01)

COVID-19: Ophthalmic prophylactic and therapeutic measures
by: Shrikant Waikar, et al.
Published: (2020-01-01)

Treating with besifloxacin for acute bacterial conjunctivitis: a Meta-analysis
by: Jun-Jie Wang, et al.
Published: (2019-12-01)

Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
by: Timothy L Comstock, et al.
Published: (2010-03-01)

The incidence of infection in routine knee arthroscopy without the use of prophylactic antibiotics is low
by: Mun Chun Lai, et al.
Published: (2019-06-01)

Survey of Japanese ophthalmic surgeons regarding perioperative disinfection and antibiotic prophylaxis in cataract surgery
by: Matsuura K, et al.
Published: (2014-09-01)

Curative effect of pranoprofen eye drops with tobramycin and dexamethasone ophthalmic suspension for cataract patients after surgery
by: Jiang-Song Feng, et al.
Published: (2017-09-01)

An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical Outcomes
by: Barry A. Schechter, et al.
Published: (2019-11-01)

Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension
by: Bruce I Gaynes, et al.
Published: (2008-06-01)

Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration
by: Gail Torkildsen, et al.
Published: (2010-04-01)

Prophylactic ophthalmic bethametazone for sulfur mustard-induced ocular Injury
by: Mostafa Naderi, et al.
Published: (2009-09-01)

Development of ophthalmic training simulator for cataract surgery
by: Kumova S.V., et al.
Published: (2017-06-01)

Impact of Ophthalmic Viscosurgical Devices in Cataract Surgery
by: Monali S. Malvankar-Mehta, et al.
Published: (2020-01-01)

In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride
by: Joseph Blondeau, et al.
Published: (2021-05-01)

Effect of Cyclosporine 0.09% Treatment on Accuracy of Preoperative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery
by: Hovanesian JA, et al.
Published: (2021-09-01)

Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies
by: Singh RP, et al.
Published: (2017-05-01)

The anti-cataract molecular mechanism study in selenium cataract rats for baicalin ophthalmic nanoparticles
by: Li N, et al.
Published: (2018-05-01)

The value and implementation of routine ophthalmic examination in the era of HAART
by: Wangting Li, et al.
Published: (2021-01-01)

Prophylactic Antibiotics and Wound Infection
by: Abubaker Ibrahim Elbur, et al.
Published: (2013-12-01)

Prophylactic antibiotics and percutaneous nephrolithotomy
by: Beuy Joob, et al.
Published: (2017-01-01)

Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical “Pulse” Dose
by: Steven M. Silverstein
Published: (2019-09-01)

Cost-utility of routine cataract surgery
by: Ryynänen Olli-Pekka, et al.
Published: (2006-09-01)

Prophylactic intracameral levofloxacin in cataract surgery – an evaluation of safety
by: Espiritu CR, et al.
Published: (2017-12-01)

Are prophylactic antibiotics necessary for urodynamic study?
by: Cenk Gürbüz, et al.
Published: (2013-06-01)

Prophylactic antibiotic: The need for clear guidelines
by: Mohammed Mahdi Muqarmea
Published: (2013-01-01)

Vesicoureteral reflux and continuous prophylactic antibiotics
by: Ted Lee, et al.
Published: (2017-06-01)

Prophylactic antibiotics for tubeless percutaneous nephrolithotomy
by: Chih-Yu Yang, et al.
Published: (2017-01-01)